These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 15670193

  • 1. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism.
    Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U, Facchetti M, Beck-Peccoz P.
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):176-81. PubMed ID: 15670193
    [Abstract] [Full Text] [Related]

  • 2. Macro- and microadenoma of thyrotropin secreting pituitary tumors--two clinical cases.
    Hubalewska-Hola A, Fröss K, Kostecka-Matyja M, Sowa-Staszczak A, Szybiński Z, Huszno B, Ptak M.
    Przegl Lek; 2003 Feb; 60(11):768-71. PubMed ID: 15058054
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

  • 4. [Monosymptomatic hyperthyroidism and TSH-producing adenoma: successful therapy with octreotide].
    Mayinger B, Axelos D, Pavel M, Hahn EG, Hensen J.
    Dtsch Med Wochenschr; 1999 Jan 29; 124(4):73-8. PubMed ID: 10071603
    [Abstract] [Full Text] [Related]

  • 5. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
    Yoenem A, Cakyr B, Azal O, Corakcy A, Kutlu M, Oezata M.
    Endocr Regul; 1999 Dec 29; 33(4):169-74. PubMed ID: 10700085
    [Abstract] [Full Text] [Related]

  • 6. Thyrotropin-secreting pituitary adenomas: biological and molecular features, diagnosis and therapy.
    Losa M, Fortunato M, Molteni L, Peretti E, Mortini P.
    Minerva Endocrinol; 2008 Dec 29; 33(4):329-40. PubMed ID: 18923369
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
    Zhang CF, Liang D, Zhong LY.
    Chin Med J (Engl); 2012 Aug 29; 125(15):2758-63. PubMed ID: 22931988
    [Abstract] [Full Text] [Related]

  • 8. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug 29; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
    Clin Endocrinol (Oxf); 2007 Aug 29; 67(2):310-5. PubMed ID: 17555503
    [Abstract] [Full Text] [Related]

  • 13. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
    Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM.
    Clin Endocrinol (Oxf); 1994 Mar 29; 40(3):421-8. PubMed ID: 8187308
    [Abstract] [Full Text] [Related]

  • 14. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995.
    Beck-Peccoz P, Mariotti S, Guillausseau PJ, Medri G, Piscitelli G, Bertoli A, Barbarino A, Rondena M, Chanson P, Pinchera A.
    J Clin Endocrinol Metab; 1989 Jan 29; 68(1):208-14. PubMed ID: 2491862
    [Abstract] [Full Text] [Related]

  • 15. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue.
    Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD.
    N Engl J Med; 1987 Jul 02; 317(1):12-7. PubMed ID: 2884564
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
    Williams G, Anderson JV, Williams SJ, Bloom SR.
    Acta Endocrinol Suppl (Copenh); 1987 Jul 02; 286():26-36. PubMed ID: 2892335
    [Abstract] [Full Text] [Related]

  • 18. TSH producing pituitary tumor: biochemical diagnosis and long-term medical management with octreotide.
    Chayen SD, Gross D, Makhoul O, Glaser B.
    Horm Metab Res; 1992 Jan 02; 24(1):34-8. PubMed ID: 1612557
    [Abstract] [Full Text] [Related]

  • 19. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F, Magony S, Julesz J.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [Abstract] [Full Text] [Related]

  • 20. [Thyroid-stimulating hormone hypophyseal adenoma. A case report].
    Gannage MH, Maacaron C, Okais N, Halaby G.
    J Med Liban; 1997 May 12; 45(2):97-101. PubMed ID: 9289506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.